Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 599

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 599
---
F-101 Notes to Combined Financial Statements (Amounts in US Dollars, except otherwise indicated) 22.Events after the reporting period Management has evaluated subsequent events through January22, 2025, the date on which these combined financial statements were issued. New Disbursement:and Addenda under existing loan agreements Intercompany Loan Agreement with Heritas Ltd: Subsequent to June 30, 2024, the Parent provided financing to the Group amounting to US$47,693, under the agreement mentioned in Note 12 — Borrowings with third and related parties, Loans from related parties, Heritas Ltd Loan Agreement, point 2). Additional Financing to Heritas Argentina: Subsequent to June 30, 2024, Heritas Argentina received additional funding of US$69,863 from Heritas Ltd., US$215,322 from Bioceres S.A., and U$S29,762 from CIBIC pursuant to loan agreements executed prior to the reporting date, maintaining the same conditions. For further details, see Note 12 — Borrowings with third and related parties and 20 — Related parties. Loan Amendments and Credit Line Extensions: On October 23, 2024, Heritas Argentina amended its existing loan agreements with CIBIC and Bioceres S.A. (see Note 12 — Borrowings) to incorporate credit line extensions. These amendments allow for additional financing of up to US$100,000 from each lender. Shareholders and Business Combination Agreement On August 27, 2024, Heritas Ltd, and MultiplAI Health Ltd. mutually agreed to terminate the Amended and Restated Share Purchase Agreement (SPA) originally executed on March 13, 2024, thereby terminating MultiplAI Health Ltd,’s participation in the Business Combination Agreement dated March 25, 2024. Subsequently, OmnigenicsAI Corp signed a notice of termination. This decision was made following a detailed evaluation of the financial and operational risks inherent in the integration process, as well as the recent regulatory changes issued by the U.S. FDA in May 2024 concerning Laboratory Developed Tests (LDTs), which directly impacted MultiplAI Health Ltd.’s compliance and market strategy in the U.S.. The termination of the SPA is intended to safeguard the strategic interests of Heritas Ltd., OmnigenicsAI Corp, and their shareholders. Upon execution of this termination agreement, all rights and obligations outlined in the SPA and related transaction documents ceased, ensuring the protection of the involved parties’ interests and compliance with